One way of achieving this goal could be to devote efforts for education [203], technology transfer and the production of new monoclonal antibodies against mutated epitopes that may serve as surrogates for molecular studies, as those we now use to diagnose some entities, such as NPM1-mutated AML [204] or ALK+ anaplastic large cell lymphoma [205]. This evidence concerns the gene ALK and acute myeloid leukemia.